Roles of Ki-67 and p16 as biomarkers for unknown primary head and neck squamous cell carcinoma
Treatment guidelines have not been established for unknown primary head and neck squamous cell carcinoma (SCC). For these patients, chemoradiotherapy (CRT) can provide a better prognosis than that for patients with other head and neck cancers. The presence of HPV in the tumor is associated with a better outcome. However, not all patients with HPV-positive unknown primary head and neck SCC experience good treatment outcomes in actual clinical settings.
We thus retrospectively determined the Ki-67 proliferation index and p16 expression status to assess the associations of these parameters with treatment outcomes of patients with unknown primary head and neck SCC.
The subjects were 13 patients who underwent CRT after surgery or excision biopsy between 1999 and 2016. The 2- and 5-year overall survival (OS) rate was 76.9% and 68.4%, respectively. The prognostic factor was age. There was no significant difference in survival between patients with a high Ki-67 vs. low Ki-67 or between patients with p16-positive vs. p16-negative metastases OS. However, all p16-positive patients with low Ki-67 showed good locoregional control.
The combination of ki67 expression and p16 expression status may allow prediction of local control more accurately than p16 expression status alone.
KeywordsUnknown primary head and neck squamous cell carcinoma Chemoradiotherapy Ipsilateral oropharynx and neck irradiation p16 Ki-67
The authors thank Bierta Barfod for her contribution to the language editing of this manuscript.
No specific funding was received for this research.
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Ethical approval retrospective studies
This study was approved by the institutional review board, and patient informed consent was obtained. (Trial registration number: Nihon University Itabashi Hospital Clinical Research Center RK-170214-9).
Informed consent was obtained from all individual participants included in the study. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article. Documentation of informed consent for treatment was signed by each patient and placed in the patient’s medical record.
Research data policy
The dataset supporting the conclusions of this article is included within the article.
Consent for publication
copy of the written consent is available for review by the Editor-in-Chief of this journal.
- 5.Kimple RJ, Harari PM (2014) Is radiation dose reduction the right answer for HPV-positive head and neck cancer? Oral Oncol 50:560–564. https://doi.org/10.3978/j.issn.2305-5839.2015.01.37 CrossRefGoogle Scholar
- 10.Werner JA, Dünne AA (2001) Value of neck dissection in patients with squamous cell carcinoma of unknown primary. Onkologie 24:16–20Google Scholar
- 14.Ligey A, Gentil J, Créhange G et al (2009) Impact of target volumes and radiation technique on loco-regional control and survival for patients with unilateral cervical lymph node metastases from an unknown primary. Radiother Oncol 93:483–487. https://doi.org/10.1016/j.radonc.2009.08.027 CrossRefGoogle Scholar
- 20.National Cancer Institute Common terminology criteria for adverse events v4.0 (CTCAE) (2016) http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcae_4_with_lay_terms.pdf. Accessed 12 November 2017
- 21.RTOG 1016 Protocol Information (2016) Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer Radiation Therapy Oncology Group. https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1016. Accessed 11 May 2018
- 22.Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML (2012) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35. https://doi.org/10.1056/NEJMoa0912217 CrossRefGoogle Scholar
- 23.Park GC, Lee M, Roh JL et al (2012) Human papillomavirus and p16 detection in cervical lymph node metastases from an unknown primary tumor. Oral Oncol 48:1250–1256. https://doi.org/10.1016/j.oraloncology.2012.05.026 CrossRefGoogle Scholar
- 32.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidlines®) Senior adult oncology Version 2.2014. © 2014 National Comprehensive Cancer Network, Inc. NCCN.org. Accessed 1 Nov 2018Google Scholar